China
Africa
Explore chapters and articles related to this topic
Lifestyle and Its Relationship to Pain
Published in Sahar Swidan, Matthew Bennett, Advanced Therapeutics in Pain Medicine, 2020
Saccharin (ortho-sulfobenzoic acid imide) has also shown to alter intestinal bacteria and change the microbiome. A mice study reported in 2017 showed the induction of liver inflammation, perhaps associated with the perturbation of the gut microbiota.33 Newer technology is allowing study of the microbiome and a relationship to pain conditions. One such relationship has been shown with chronic prostatitis and chronic pelvic pain syndrome.34
The prostate and seminal vesicles
Published in Professor Sir Norman Williams, Professor P. Ronan O’Connell, Professor Andrew W. McCaskie, Bailey & Love's Short Practice of Surgery, 2018
Professor Sir Norman Williams, Professor P. Ronan O’Connell, Professor Andrew W. McCaskie
This diagnosis is made by the presence of perigenital pain in the absence of any objective evidence of prostatic inflammation. Whether the syndrome has any relationship with the prostate is unclear. The syndrome is part of the chronic pelvic pain syndrome spectrum.
Ciprofloxacin
Published in M. Lindsay Grayson, Sara E. Cosgrove, Suzanne M. Crowe, M. Lindsay Grayson, William Hope, James S. McCarthy, John Mills, Johan W. Mouton, David L. Paterson, Kucers’ The Use of Antibiotics, 2017
Jason Kwong, M. Lindsay Grayson
Chronic prostatitis/chronic pelvic pain syndrome is a condition of unknown etiology defined by pelvic pain of more than 3 months’ duration. Therapies are empirical and mostly untested and, although there has been no clear evidence to support an infective etiology, antibiotics are frequently prescribed. In one study involving 196 men diagnosed with this condition and a mean duration of symptoms of 6.2 years, ciprofloxacin 500 mg twice daily for 6 weeks demonstrated no advantage over either tamsulosin or placebo (Alexander et al., 2004). Thus, long-term ciprofloxacin should not be recommended for this complex pain syndrome.
Results of purified micronized flavonoid fraction in the treatment of categorized type III chronic pelvic pain syndrome: a randomized controlled trial
Published in The Aging Male, 2020
Aytac Sahin, Musab Ali Kutluhan, Caglar Yildirim, Ahmet Urkmez, Serkan Akan, Ayhan Verit
Various studies on different subgroups of chronic prostatitis and chronic pelvic pain syndrome do not provide clear and strong evidence regarding treatment modalities. Even detailed literature reviews or meta-analyses, in which these studies are evaluated, prefer to make recommendations combined with expert opinion. The main reason for this is the fact that the pathophysiology of CPPS is still not fully understood. Treatment goals are not clear, and treatment is still very difficult. Based on the findings of our study, we think that the use of purified micronized flavonoid will decrease prostatic inflammation occurring due to increased perineal venous return. Furthermore, it can also be preferred as part of multimodal therapy because of its profile with relatively less side effects and being more affordable compared with alpha-blockers. It can especially be more effective when combined therapy is administered or when it is used together with alpha-blockers. Therefore, future studies with a higher number of patients are needed.
Increased risk of prostatitis in male patients with depression
Published in The World Journal of Biological Psychiatry, 2020
Chi-Shun Lien, Chi-Jung Chung, Cheng-Li Lin, Chao-Hsiang Chang
Prostatitis accounts for 8% of the cases in urology outpatient clinics and causes lifetime suffering of approximately 16% of men in the United States. According to the National Institutes of Health’s consensus classification, prostatitis is divided into four categories: acute bacterial prostatitis, chronic bacterial prostatitis, chronic prostatitis/pelvic pain syndrome (CP/CPPS), and asymptomatic inflammatory prostatitis. Acute bacterial prostatitis is an acute urinary tract infection related to the prostate. Chronic bacterial prostatitis is a recurrent urinary tract infection with the same bacteria cultured in prostatic secretions during asymptomatic periods (Krieger et al. 1999). Approximately 10% of men with acute prostatitis will eventually develop chronic prostatitis. Similarly, chronic prostatitis comprises approximately 10% of all prostatitis cases (Krieger and Egan 1991). The guideline defines CP/CPPS as that which presents chronic pelvic pain and possible voiding symptoms without the evidence of infection (Nickel et al. 1999). The aetiology of chronic prostatitis and chronic pelvic pain syndrome is poorly understood but may involve an infectious or inflammatory initiator that results in neurological injury, and eventually in pelvic floor dysfunction in the form of increased pelvic tone (Murphy et al. 2009). One study also found that the synergistic interaction of benign prostatic hyperplasia and prostatitis is a risk factor for prostate cancer (Hung et al. 2013).
Effectiveness of external myofascial mobilisation in the management of male chronic pelvic pain of muscle spastic type: A retrospective study
Published in Arab Journal of Urology, 2021
M. S Ajimsha, Laith Ahmad Ismail, Noora Al-Mudahka, Ahmad Majzoub
Chronic pelvic pain syndrome is a common but debilitating chronic condition that affects men and women, and results in significant economic burdens and healthcare costs. The anecdotal evidence of the effectiveness of EMM for CPPS is receiving a great deal of attention and the present study provides proof of concept for its effectiveness. The EMM may be an effective therapeutic supplement for the muscle spastic type of CPPS. The sustainability of long-term effects and outcomes remains to be determined. Future prospective and blinded, randomised studies with adequate sample size and long-term follow-up are needed to ascertain the above findings and to predict characteristics of men who would respond to the EMM therapy.